Literature DB >> 15155773

Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination.

Sonia López-Giral1, Nuria E Quintana, María Cabrerizo, Manuel Alfonso-Pérez, Mónica Sala-Valdés, Valle Gómez Garcia De Soria, José María Fernández-Rañada, Elena Fernández-Ruiz, Cecilia Muñoz.   

Abstract

B cell neoplasms present heterogeneous patterns of lymphoid organ involvement, which may be a result of the differential expression of chemokine receptors. We found that chemokine receptor (CCR)7, CXC chemokine receptor (CXCR)4, or CXCR5, the main chemokine receptors that mediate B cell entry into secondary lymphoid tissues and their homing to T cell and B cell zones therein, were highly expressed in B malignancies with widespread involvement of lymph nodes. Conversely, those pathologies with little or no nodular dissemination showed no expression to very low levels of CCR7 and CXCR5 and low to moderate levels of CXCR4. These findings provide evidence for the role of CCR7, CXCR4, and CXCR5 in determining the pattern of lymphoid organ involvement of B tumors. Functional studies were performed on B malignancies expressing different levels of CCR7, CXCR5, and CXCR4. Multiple myeloma (MM) cells did not express CCR7 nor CXCR5 and did not migrate in response to their ligands; a moderate expression of CXCR4 on MM cells was accompanied by a migratory response to its ligand, CXCL12. By contrast, cells from B cell chronic lymphocytic leukemia (B-CLL) expressed the highest levels of these chemokine receptors and efficiently migrated in response to all ligands of CCR7, CXCR4, and CXCR5. In addition, the migration index of B-CLL cells in response to both of the CCR7 ligands correlated with the presence of clinical lymphadenopathy, thus indicating that the high expression of functional chemokine receptors justifies the widespread character of B-CLL, representing a clinical target for the control of tumor cell dissemination.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15155773     DOI: 10.1189/jlb.1203652

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  52 in total

1.  Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation.

Authors:  Shaun Rosebeck; Lisa Madden; Xiaohong Jin; Shufang Gu; Ingrid J Apel; Alex Appert; Rifat A Hamoudi; Heidi Noels; Xavier Sagaert; Peter Van Loo; Mathijs Baens; Ming-Qing Du; Peter C Lucas; Linda M McAllister-Lucas
Journal:  Science       Date:  2011-01-28       Impact factor: 47.728

2.  Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.

Authors:  Yazan Alsayed; Hai Ngo; Judith Runnels; Xavier Leleu; Ujjal K Singha; Costas M Pitsillides; Joel A Spencer; Teresa Kimlinger; Joanna M Ghobrial; Xiaoying Jia; Ganwei Lu; Michael Timm; Ashok Kumar; Daniel Côté; Israel Veilleux; Karen E Hedin; G David Roodman; Thomas E Witzig; Andrew L Kung; Teru Hideshima; Kenneth C Anderson; Charles P Lin; Irene M Ghobrial
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

3.  Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation.

Authors:  Silvia Deaglio; Fabio Malavasi
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

4.  Multifocal CNS infiltration of chronic lymphocytic leukemia in the form of small-cell solid metastatic lesions.

Authors:  Jaime Imitola; Kelly Pitt; James L Peoples; Barbara Krynska; Hina Sheikh; Santosh Kesari; S Ausim Azizi
Journal:  J Neurooncol       Date:  2012-05-10       Impact factor: 4.130

5.  WNT5A: a motility-promoting factor in Hodgkin lymphoma.

Authors:  F Linke; S Zaunig; M M Nietert; F von Bonin; S Lutz; C Dullin; P Janovská; T Beissbarth; F Alves; W Klapper; V Bryja; T Pukrop; L Trümper; J Wilting; D Kube
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

6.  CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia.

Authors:  Mercedes Borge; Paula Romina Nannini; Jeremías Gastón Galletti; Pablo Elías Morande; Julio Sánchez Avalos; Raimundo Fernando Bezares; Mirta Giordano; Romina Gamberale
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

Review 7.  Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy.

Authors:  Victoria Wu; Huwate Yeerna; Nijiro Nohata; Joshua Chiou; Olivier Harismendy; Francesco Raimondi; Asuka Inoue; Robert B Russell; Pablo Tamayo; J Silvio Gutkind
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

Review 8.  The role of G protein-coupled receptors in lymphoid malignancies.

Authors:  Adrienne Nugent; Richard L Proia
Journal:  Cell Signal       Date:  2017-08-09       Impact factor: 4.315

9.  Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma.

Authors:  Zhuqing Li; Sankaranarayana P Mahesh; De Fen Shen; Baoying Liu; Willie O Siu; Frank S Hwang; Qing-Chen Wang; Chi-Chao Chan; Ira Pastan; Robert B Nussenblatt
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

10.  In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia.

Authors:  Carlo Calissano; Rajendra N Damle; Gregory Hayes; Elizabeth J Murphy; Marc K Hellerstein; Carol Moreno; Cristina Sison; Matthew S Kaufman; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2009-09-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.